

Imaging in Oncology Trials

Delivering best-in-class imaging services and expertise to clinical sponsors worldwide



Contents

Artificial Intelligence is our DNA 1
Transforming the science of
medical imaging

Creating value from medical images:
our two Business Units

A world-class imaging partner 2

The Median advantage 4
People pushing the boundaries of
imaging technology

A smart, proactive and responsive team
backed-up with in-house experts

**A blend of sciences, technology,
clinical expertise, and operational
excellence** 5

**Cancer therapy and immuno-
therapy clinical trials using Median** 6
Facts and figures

**Experience by primary cancer
indication** 7
156 studies

**Median Technologies can help
deliver for your oncology trials** 8
Our expertise and end-to-end imaging
services are tailored to your studies

Artificial Intelligence is our DNA

Transforming the science of medical imaging

Medical images reveal the disease as it really is, at every stage and allow to monitor its evolution in a non-invasive manner. Harnessing the true power of medical images is key to accelerate clinical innovations, drug development and improve patient care.

Since 2002, we harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Creating value from medical images: our two Business Units

3 core areas of expertise


- Medical Imaging
- Clinical trials
- Oncology and other life-threatening diseases

4 technology pillars

- Advanced analytics
- Imaging technology
- AI/ML tech
- Cloud and On-premise solutions




iCRO: Imaging solutions and services for oncology trials, based on the iSee® imaging platform



iBiopsy®: Fully automatic AI/ML tech-based SaMD to aid the identification of cancers and life-threatening diseases onset at earliest stage, allowing a better patient care

A world-class imaging partner



3

Offices: Boston, USA – Sophia Antipolis, France
– Shanghai, China

180+

Employees*

2,400+

Working with 2,400+ investigator sites*


40+

Biopharma Clients in the US and Europe*

10+

Biopharma Clients in China*

* As of December 2021



Median delivers on a global scale. Our reach stretches from the USA, the world’s largest healthcare and drug development market, across Europe, and into Asia, an increasingly important region for clinical development and healthcare markets.

As an iCRO, we deliver end-to-end imaging services for Phase I – Phase III clinical trials and are committed to top quality and operational excellence. Our focus is oncology, a therapeutic area representing the widest proportion of clinical trials worldwide; we have developed a considerable expertise in the field. We work with sponsors of all sizes, from major pharma organizations to small- and medium-size biotech companies. Our footprint is global. With our offices in Europe, the US and China, we deliver globally, providing best-in-class imaging services to our biopharma clients. We also partner with major Contract Research Organizations (CRO), for whom our imaging solutions complement their traditional clinical trial expertise. We are currently working with 2,400+ investigator sites through the world and more than 50+ biopharma sponsors.

Number of sites

- 201 +
- 101-200
- 51-100
- 21-50
- 1-20

The Median advantage

People pushing the boundaries of imaging technology

Median has unmatched clinical, technology and operational expertise in oncology trials. Our talented, dedicated people keep pushing the boundaries of what our unique, specialist knowledge and technologies can achieve.

Our efforts are changing the way images are used in clinical trials; extracting the highest quality, most advanced non-invasive imaging biomarkers so it becomes the standard for developing new therapies, diagnosing diseases and treating patients.

When you work with us, you benefit from a senior level team who stays with you every step of the way throughout your trial. We always remain flexible and adaptable to best serve your needs, be it offering transparency to your project and data, or proactive support. In fact, we pride ourselves on high engagement and flexibility from our small dedicated team approach. As of December 2021, our company numbers 180+ employees worldwide with R&D totalling 25% of the total headcount.

In our day-to-day work, there is no greater satisfaction than making a difference that has the potential to help save or improve the lives of millions of people.


Our values

As individuals and as a team, we are guided by four core values that are essential to us: leading health innovation with purpose, committing to quality in all we do, supporting our customers in achieving their goals, and putting the patient first. These values define who we are, what we do, the way we do it, and what we, as Median Technologies, aspire to. We strive to apply these values in the relationships we have with one another, our customers and partners, and the solutions we provide. This is what it means to be a part of Median Technologies.

Read more:

mediantechnologies.com/our-core-values/

A smart, proactive and responsive team backed-up with in-house experts



A blend of sciences, technology, clinical expertise, and operational excellence

An experienced medical team

As part of the Medical Affairs department, our medical team is key for our iCRO activities. Placed under the responsibility of our CMO, the medical team supports all operations from RFPs to study close-out. The team is responsible for providing key expertise on protocol design and imaging criteria selection, mostly at the beginning of studies. Reader selection, training, ongoing quality monitoring (based on intra- and inter-reader variability measurements) are also under his/her responsibility.

In addition to board certified radiologists, Median's medical team includes lead scientists, who collaborate whenever possible with sponsors, and identify potential scientific publications to be presented in international conferences and meetings – i.e., ASCO, ESMO, RSNA and ESR annual meetings, and peers reviewed articles.

Empower your oncology trials with Artificial Intelligence

At Median, we harness the power of medical images by using advanced AI technologies to provide insight into novel therapies for patients. We established our Imaging Lab to deliver additional metrics and analysis for better understanding drug profiles by leveraging artificial intelligence technologies. Using AI can assist you to:

- Triage patients
- Predict response to therapy
- Assess drug effects in advance
- Improve drug safety

iSee®, our unique and proprietary imaging platform

Median is at the heart of innovative imaging solutions with iSee®, our oncology-focused image analysis and data management software. This innovative software is advancing the development of new drugs. iSee® helps radiologists automatically identify, quantify, and track lesions across time points. All our readers use iSee®, accessed through a web-browser for all imaging projects we manage.

Description (Unit)	Prior	Current	Follow-up
Segmentation method	Nodule	Nodule	
Elapsed time (days)			92
Doubling time (days)			293
Volume (mm ³)	430.3	535.0	24.3%
✓ Axial LD (mm)	10.3	11.6	11.8%
✓ Width (mm)	8.1	9.1	12.0%
Max attenuation (HU)	119	165	
Type	Pulmonary	Pulmonary	
Attenuation	Solid	Solid	
Surrounding	Juxtavas...	Juxtavas...	

iSee®

- Limits reader subjectivity
- Increases accuracy and reproducibility
- Reduces inter-reader variability
- Streamlines data management
- Decreases data queries
- Provides both routine and advanced imaging biomarkers
- Delivers superior reporting

Operational excellence and quality are at the core of everything we do at Median

We leverage our experience, know-how, and technology in each area of clinical development:

Regulatory compliance and quality:

Our team has extensive practical knowledge of clinical trial regulatory requirements for image management. Our clinical services and technology platform iSee® comply with ICH/GCP guidelines, FDA, EMA and NMPA regulations, and clinical study protocols.

Project management: Our team includes collaboration professionals with a thorough understanding of project management practices, tools, and skills. Our project management processes and practices are derived from the international PMI standard and adapted to specific clinical trial requirements.

Data management and quality control:

Our iSee® platform provides structured image and lesion data handling. Our automated and standardized processes enforce image management and quality control with automated checks conducted as early as possible and throughout the entire data collection process using iSee®. Our solutions provide seamless, automated interoperability with clinical trial management and electronic data collection systems.

Biostatistics and data analysis: Median provides significant data analysis and biostatistics capabilities, including know-how, tools, and methodology, for use in our customers' clinical trials.

IT capabilities: Our cloud-based IT infrastructure is optimized to increase uptime, while our remote data centers provide power and connection redundancies, ensuring continuity of operations and scalable services.

Cancer therapy and immunotherapy clinical trials using Median

108

Early phase trials
Including 48 trials with Immunotherapy

48

Late phase trials
Including 36 trials with Immunotherapy

3

Successful FDA inspections
2017, 2019 and 2021

5

Successful NMPA Inspection
2020 and 2021

10

Supported Regulatory approvals


22,224

Enrolled patients

Early and late phase trials numbers refer to cumulative contracted/awarded studies since the beginning of the iCRO activity, with awards of less than 12 months. All numbers are as of December 2021.

Experience by primary cancer indication

156 studies



Key

- IO studies
- Other studies (non IO)

Cumulative contracted/awarded studies since the beginning of the iCRO activity, and until 12/31/2021, with awards of less than 12 months.

Median Technologies can help deliver for your oncology trials

Our expertise and end-to-end imaging services are tailored to your studies

We extract the utmost meaningful information from medical images

Median's imaging platform iSee® provides automated and standardized image analysis.

iSee® covers a wide range of cancer indications (solid tumors).

iSee® provides expert oversights of images, standardizing lesion detection, selection, quantification and tracking.

iSee® extracts standard and novel biomarkers.

iSee® provides multiple imaging criteria, from RECIST 1.1 to more specific criteria such as mRECIST or iRECIST.

What does this mean for your study?

- More meaningful data from an image
- Highest quality data for better informed decisions including Go/NoGo decisions
- Increased data statistical power by limiting reading variability and increasing reproducibility of measures

We provide a unique scientific and medical expertise

We deliver imaging expertise for oncology trials from phase I to phase III.

We focus on the evaluation of new oncology drugs including immuno-oncology drugs, and provide a high level of customization, depending on your trials and objectives.

We have a strong expertise in imaging protocol design and adapt reading design to protocol.

Our expertise covers a wide range of imaging criteria such as RECIST, iRECIST, mRECIST, irRC, RECIL, Lugano or RANO.

As a developer of cutting-edge imaging technologies, we pioneer the use of high-tech such as AI, or radiomics for image analysis in clinical trials.

What does this mean for your study?

- 100% tailored imaging protocol design
- Enriched information for subsequent development phases or other trials through side by side comparison of routine and advanced imaging biomarkers
- Improved drug evaluation using emerging technologies and notably AI technologies
- Joint promotion of study results and scientific advances in scientific journals and conferences

We manage end-to-end imaging workflows

Our service offer covers the full range of all you need to manage images in your oncology trials.

We deliver end-to-end imaging workflows:

- Study start up
- Image and clinical data management
- Scientific consulting
- Reader services, independent reviews
- Image data processing and site support
- Study close-up

What does this mean for your study?

- Configurable software and flexible workflows quickly tailored to align with your operations and to match the needs of the trial
- Our small, dedicated, and experienced teams provide flexible, adaptable level of service for your project

We implement stringent reading process

By utilizing a limited reader pool, we ensure high quality without compromising productivity.

Our network of readers includes only independent board-certified radiologists in the US, EU and China.

All our readers are trained to GCP/CFR21 part 11, and study specifics, through clinical/technical sessions.

Our reader processes are adapted to each trial and strictly monitored.

We cover all reading designs based on protocol (Collect & Hold, Single or Double Independent Central Reviews) and implement strong rules to ensure quality.

What does this mean for your study?

- For each study, reader selection according to their expertise in the indication, experience, monitoring results and workload
- Design and monitoring adapted to each trial and strictly monitored

We provide online reporting tool for your studies

The Median Online Reporting Portal (ORP) is a configurable system providing ongoing status/metrics on studies.

Each report provides status and performance metrics, evolution charts, data trackers that can be filtered and exported.

The ORP includes four specific reports to monitor four main activities:

- Site management
- Images collection
- Queries management
- Reads management

The ORP can be used by sponsors and Median project management teams.

What does this mean for your study?

- Dedicated tracking access to your images and data
- Transparency to project and data

We place quality at the core of everything we do

We apply stringent quality control processes that go beyond the industry standards.

Our dedicated QA team has an international coverage.

Our senior PMs are PMP® certified.

All our operations teams are trained (and regularly retrained) on GCP/CFR21 part 11.

In 2017, 2019 and 2021, we have successfully completed three FDA audits. We have also passed 5 NMPA audits between 2020 and 2021. Health authorities inspections are a daunting challenge for any provider, but we see them as an opportunity for continuous improvement.

On average, we are audited by our clients more than 10 times a year, which gives our QA team a very good experience and track record

What does this mean for your study?

- Quality beyond standard QA
- Integrity of data
- Better dossiers for submission to health authorities
- Value dossiers for payers
- Dedicated experienced teams with minimal turnover delivering proactive support

[mediantechnologies.com](https://www.mediantechnologies.com)

About Us

As an imaging CRO, Median Technologies has unmatched clinical, technological and operational experience and expertise in oncology trials. With our offices based in the US, Europe and China, we operate globally to deliver best-in-class end-to-end imaging services for your Phase I to III oncology trials. We have a unique knowledge of the various standard imaging criteria used in clinical trials covering all solid tumor cancer indications, and we also provide innovative imaging biomarkers to ease Go/NoGo decisions in early phase studies. Median Technologies works with large pharma and biotech companies as well as global CROs, has a recognized track record with Phase III studies and has successfully passed FDA and China NMPA audits. We nicely complement the experience of global CROs we partner with by bringing our unique expertise in oncology imaging. We excel in all areas of managing oncologic images in clinical trials. There are many excellent reasons for selecting Median Technologies as your imaging CRO. Contact us to learn more!

[mediantechnologies.com](https://www.mediantechnologies.com)



Contact Us:

inforequest@mediantechnologies.com
www.mediantechnologies.com

Scan to find
out more:

